Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.
Olivia Main, MD
Advertisement
Olivia Main, MD is the chief fellow at NYU Grossman Long Island School of Medicine, Perlmutter Cancer Center in New York, NY.
Articles by Olivia Main, MD
Advertisement
Latest Updated Articles
T-Cell–Redirecting Strategies Emerge in Myeloma From 2025 ASCO, EHA, and IMSPublished: November 18th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5
